Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.,Antiviral Therapy

当前位置： X-MOL 学术 › Antivir. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Long-term outcomes in Chinese patients with chronic hepatitis B receiving nucleoside/nucleotide analogue therapy in real-world clinical practice: 5-year results from the EVOLVE study.
Antiviral Therapy ( IF 1.2 ) Pub Date : 2020-10-22 , DOI: 10.3851/imp3372
Jidong Jia ₁ , Jia Shang ₂ , Hong Tang ₃ , Jiaji Jiang ₄ , Qin Ning ₅ , Xiaoguang Dou ₆ , Shuqin Zhang ₇ , Mingxiang Zhang ₈ , Tao Han ₉ , Deming Tan ₁₀ , Xinmin Zhou ₁₁ , Guoliang Chen ₁₂ , Jifang Sheng ₁₃ , Zhijun Su ₁₄ , Haijun Chen ₁₅ , Erhei Dai ₁₆ , Yinong Ye ₁₇ , Ying Guo ₁₈ , Yuefei Shen ₁₉ , Jing Yuan ₂₀ , Zhen Wei ₂₁ , Siyun Zhu ₂₂ ,

Affiliation

Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Henan Provincial People's Hospital, Zhengzhou, China.
West China Hospital, Sichuan University, Chengdu, China.
The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Affiliated Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Shengjing Hospital of China Medical University, Shenyang, China.
Hepatology Hospital of Jilin, Changchun, China.
The Sixth People's Hospital of Shenyang, Shenyang, China.
Tianjin Third Central Hospital, Tianjin, China.
Xiangya Hospital of Central South University, Changsha, China.
Xijing Hospital, Xi'an, China.
Xiamen Chinese Medical Hospital, Xiamen, China.
The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
The First Hospital of Quanzhou, Quanzhou, China.
Jinhua Central Hospital, Jinhua, China.
The Fifth Hospital of Shijiazhuang, Shijiazhuang, China.
The First People's Hospital of Foshan, Foshan, China.
Taiyuan The Third People's Hospital, Taiyuan, China.
The First People's Hospital of Xiaoshan District, Hangzhou, China.
The Third People's Hospital of Shenzhen, Shenzhen, China.
GCP ClinPlus Co., Ltd, Beijing, China.
Bristol-Myers Squibb, Shanghai, China.

In China, the optimal management of individuals living with chronic HBV infection remains an unmet need. The EVOLVE was a 5-year prospective, longitudinal, observational study that compared the clinical outcomes in treatment-naïve CHB patients receiving entecavir (ETV) or lamivudine (LAM)-based therapies.

更新日期：2020-10-27

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>